SPO11 and Parkinson disease: No differentially methylated CMRs overlapped between the female- and male-specific analyses, and all CMRs differentially methylated by PD status in females except for three (chr3:137228231–137228637, SPO11, and ASRGL1) had little or no effect in the opposite sex (Supplementary Fig. 2).